幽门螺杆菌感染 中国就医指南

Helicobacter pylori (H. pylori) infection is a chronic bacterial colonization of the gastric mucosa, primarily affecting the stomach and duodenum. First identified in 1982 by Barry Marshall and Robin Warren, this gram-negative, microaerophilic, spiral-shaped bacterium survives the acidic gastric environment by producing urease—an enzyme that hydrolyzes urea into ammonia and carbon dioxide, thereby neutralizing local acidity. Pathogenesis involves bacterial adhesion to gastric epithelial cells via adhesins (e.g., BabA, SabA), induction of inflammation through virulence factors (notably CagA and VacA), disruption of tight junctions, oxidative stress, and progressive mucosal injury. Over time, persistent infection can lead to chronic gastritis, peptic ulcer disease (PUD), gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and is classified by the WHO as a Group I carcinogen due to its strong causal association with gastric adenocarcinoma—accounting for approximately 90% of non-cardia gastric cancers. Epidemiologically, H. pylori infects nearly half the global population, with prevalence exceeding 70% in low- and middle-income countries and ranging from 20–40% in high-income nations. Infection is typically acquired in childhood, often through oral–oral or fecal–oral routes, and clusters within families and crowded living conditions. Key risk factors include poor sanitation, inadequate clean water access, lower socioeconomic status, overcrowded housing, and limited education. While many infected individuals remain asymptomatic, symptomatic patients commonly report epigastric pain, early satiety, bloating, nausea, belching, and halitosis; severe complications such as gastrointestinal bleeding, perforation, or obstruction may arise from untreated ulcers. Importantly, H. pylori infection significantly impairs quality of life—not only through physical discomfort and dietary restrictions but also via anxiety related to cancer risk, recurrent symptoms, treatment side effects (e.g., antibiotic-associated diarrhea, taste disturbances), and work absenteeism. Psychological burden—including health-related worry and reduced social engagement—is increasingly recognized in longitudinal studies. Early diagnosis—via non-invasive tests (urea breath test, stool antigen assay, serology) or invasive methods (rapid urease test, histology, culture during endoscopy)—is critical for timely eradication and prevention of long-term sequelae. Given rising global antimicrobial resistance—especially to clarithromycin, metronidazole, and levofloxacin—treatment must be tailored regionally and guided by susceptibility testing where available.

# 幽门螺杆菌感染治疗方案与费用明细（消化内科）

一、非手术/药物根除方案（一线首选）

适用人群：初治、无耐药史、无严重胃黏膜萎缩/肠化者。

• •标准四联疗法（10–14天）：PPI（如艾司奥美拉唑）+铋剂+2种抗生素（阿莫西林+克拉霉素/呋喃唑酮/四环素）

- 必查项目：幽门螺杆菌呼气试验（¹³C/¹⁴C）¥220–¥350；胃镜+活检（含快速尿素酶检测）¥650–¥1,200

• •序贯/伴同疗法（耐药高发区优选）：费用相近，检验费同上

二、二线及补救治疗方案

适用人群：首次根除失败、已知克拉霉素/甲硝唑耐药者。

• •含左氧氟沙星或利福布汀的个体化四联：药品费¥750–¥1,400；需加做粪便Hp培养+药敏试验¥1,200–¥1,800

三、特殊复杂情况处理

• •多重耐药（≥3类抗生素耐药）：推荐基于药敏的精准治疗，联合益生菌调节菌群，总疗程延长至21天；全程费用¥2,500–¥4,200（含重复呼气试验及随访）
• •伴消化性溃疡出血/重度萎缩性胃炎：需同步内镜止血或长期随访，年均随访成本¥1,000–¥1,800

四、方案快速选择指南

• •预算有限（<¥1,000）：首选国产标准四联+呼气试验（¥800–¥1,000）
• •既往失败/高耐药风险：直接行胃镜+活检+药敏（¥2,200起），避免无效用药
• •老年人/肝肾功能不全：选用阿莫西林+呋喃唑酮低风险组合，药品费¥400–¥700，强化肝肾功能监测（¥180）